Desferrioxamine-driven upregulation of angiogenic factor expression by human bone marrow stromal cells

Journal of Tissue Engineering and Regenerative Medicine

Volumn 2, Issue 5, 2008, Pages 272-278

  Potier, Esther ^a   Ferreira, Elisabeth ^a   Dennler, Sylviane ^a   Mauviel, Alain ^a   Oudina, Karim ^a   Logeart Avramoglou, Delphine ^a   Petite, Hervé ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Angiogenic factors; Bone marrow stromal cells; Desferrioxamine; HIF 1; Hypoxia; VEGF

Indexed keywords

BONE; CELLS; CYTOLOGY;

ANGIOGENIC FACTOR; BONE MARROW STROMAL CELLS; CELL/B.E; CONDITION; DESFERRIOXAMINE; HIF-1; HUMAN BONE MARROW STROMAL CELLS; HYPOXIA; UP-REGULATION; VEGF;

PROTEINS;

ANGIOGENIC FACTOR; BASIC FIBROBLAST GROWTH FACTOR RECEPTOR; DEFEROXAMINE; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN; PRIMER DNA;

ARTICLE; BONE MARROW; CONTROLLED STUDY; DRUG EFFECT; DRUG EXPOSURE; HUMAN; HUMAN CELL; HYPOXIA; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN SECRETION; STROMA CELL; UPREGULATION; BONE MARROW CELL; CYTOLOGY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANGIOGENESIS INDUCING AGENTS; BASE SEQUENCE; BONE MARROW CELLS; DEFEROXAMINE; DNA PRIMERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STROMAL CELLS; UP-REGULATION;

EID: 52649180024     PISSN: 19326254     EISSN: 19327005     Source Type: Journal    
DOI: 10.1002/term.92     Document Type: Article

References (43)

1. Ash JD, Overbeek PA. 2000; Lens-specific VEGF-A expression induces angioblast migration and proliferation and stimulates angiogenic remodeling. Dev Biol 223(2): 383-398.
2. Bang OY, Lee JS, Lee PH, et al. 2005; Autologous mesenchymal stem cell transplantation in stroke patients. Ann Neurol 57(6): 874-882.
3. Beerepoot LV, Shima DT, Kuroki M, et al. 1996; Upregulation of vascular endothelial growth factor production by iron chelators. Cancer Res 56(16): 3747-3751.
4. Brighton CT, Krebs AG. 1972; Oxygen tension of healing fractures in the rabbit. J Bone Joint Surg Am 54(2): 323-332.
5. Bruder SP, Kurth AA, Shea M, et al. 1998; Bone regeneration by implantation of purified, culture-expanded human mesenchymal stem cells. J Orthop Res 16(2): 155-162.
6. Cancedda R, Bianchi G, Derubeis A, et al. 2003; Cell therapy for bone disease: a review of current status. Stem Cells 21(5): 610-619.
7. Chekanov VS, Zargarian M, Baibekov I, et al. 2003; Deferoxamine-fibrin accelerates angiogenesis in a rabbit model of peripheral ischemia. Vasc Med 8(3): 157-162.
8. Choi EY, Kim EC, Oh HM, et al. 2004; Iron chelator triggers inflammatory signals in human intestinal epithelial cells: involvement of p38 and extracellular signal-regulated kinase signaling pathways. J Immunol 172(11): 7069-7077.
9. Dai W, Hale SL, Martin BJ, et al. 2005; Allogeneic mesenchymal stem cell transplantation in postinfarcted rat myocardium: shortand long-term effects. Circulation 112(2): 214-223.
10. Dor Y, Djonov V, Abramovitch R, et al. 2002; Conditional switching of VEGF provides new insights into adult neovascularization and pro-angiogenic therapy. EMBO J 21(8): 1939-1947.
11. FazelS, ChenL, WeiselRD, et al. 2005; Cell transplantation preserves cardiac function after infarction by infarct stabilization: augmentation by stem cell factor. J Thorac Cardiovasc Surg 130(5): 1310.
12. Ferrara N, Gerber HP, LeCouter J. 2003; The biology of VEGF and its receptors. Nat Med 9(6): 669-676.
13. Ferrari A, Hannouche D, Oudina K, et al. 2001; In vivo tracking of bone marrow fibroblasts with fluorescent carbocyanine dye. J Biomed Mater Res 56(3): 361-367.
14. Friedenstein AJ, Petrakova KV, Kurolesova AI, et al. 1968; Heterotopics of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation 6(2): 230-247.
15. Gleadle JM, Ebert BL, Firth JD, et al. 1995; Regulation of angiogenic growth factor expression by hypoxia, transition metals, and chelating agents. Am J Physiol 268(6, part 1): C1362-1368.
16. Han SK, Yoon TH, Lee DG, et al. 2005; Potential of human bone marrow stromal cells to accelerate wound healing in vitro. Ann Plast Surg 55(4): 414-419.
17. Heppenstall RB, Grislis G, Hunt TK. 1975; Tissue gas tensions and oxygen consumption in healing bone defects. Clin Orthop Relat Res 106: 357-365.
18. Jiang W, Ma A, Wang T, et al. 2006; Intravenous transplantation of mesenchymal stem cells improves cardiac performance after acute myocardial ischemia in female rats. Transpl Int 19(7): 570-580.
19. Kinnaird T, Stabile E, Burnett MS, et al. 2004a; Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. Circ Res 94(5): 678-685.
20. Kinnaird T, Stabile E, Burnett MS, et al. 2004b; Local delivery of marrow-derived stromal cells augments collateral perfusion through paracrine mechanisms. Circulation 109(12): 1543-1549.
21. Le Ricousse-Roussanne S, Barateau V, Contreres JO, et al. 2004; Ex vivo differentiated endothelial and smooth muscle cells from human cord blood progenitors home to the angiogenic tumor vasculature. Cardiovasc Res 62(1): 176-184.
22. Maire M, Logeart-Avramoglou D, Degat MC, et al. 2005; Retention of transforming growth factor β1 using functionalized dextran-based hydrogels. Biomaterials 26(14): 1771-1780.
23. Mayer H, Bertram H, Lindenmaier W, et al. 2005; Vascular endothelial growth factor (VEGF-A) expression in human mesenchymal stem cells: autocrine and paracrine role on osteoblastic and endothelial differentiation. J Cell Biochem 95(4): 827-839.
24. Nomi M, Atala A, Coppi PD, et al. 2002; Principals of neovascularization for tissue engineering. Mol Aspects Med 23(6): 463-483.
25. Ozawa CR, Banfi A, Glazer NL, et al. 2004; Microenvironmental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis. J Clin Invest 113(4): 516-527.
26. Pakala R, Watanabe T, Benedict CR. 2002; Induction of endothelial cell proliferation by angiogenic factors released by activated monocytes. Cardiovasc Radiat Med 3(2): 95-101.
27. Petite H, Viateau V, Bensaid W, et al. 2000; Tissue-engineered bone regeneration. Nat Biotechnol 18(9): 959-963.
28. Pittenger MF, Mackay AM, Beck SC, et al. 1999; Multilineage potential of adult human mesenchymal stem cells. Science 284(5411): 143-147.
29. Prockop DJ. 1997; Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 276(5309): 71-74.
30. Quarto R, Mastrogiacomo M, Cancedda R, et al. 2001; Repair of large bone defects with the use of autologous bonemarrowstromal cells. N Engl JMed 344(5): 385-386.
31. Sanchez-Ramos J, Song S, Cardozo-Pelaez F, et al. 2000; Adult bone marrow stromal cells differentiate into neural cells in vitro. Exp Neurol 164(2): 247-256.
32. Sensebe L, Mortensen BT, Fixe P, et al. 1997; Cytokines active on granulomonopoiesis: release and consumption by human marrow myoid [corrected] stromal cells. Br J Haematol 98(2): 274-282.
33. Shyu KG, Wang BW, Hung HF, et al. 2006; Mesenchymal stem cells are superior to angiogenic growth factor genes for improving myocardial performance in the mouse model of acute myocardial infarction. J Biomed Sci 13(1): 47-58.
34. Steinbrech DS, Mehrara BJ, Saadeh PB, et al. 1999; Hypoxia regulates VEGF expression and cellular proliferation by osteoblasts in vitro. Plast Reconstr Surg 104(3): 738-747.
35. Toma C, Pittenger MF, Cahill KS, et al. 2002; Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation 105(1): 93-98.
36. Tomita S, Li RK, Weisel RD, et al. 1999; Autologous transplantation of bone marrow cells improves damaged heart function. Circulation 100(19 suppl): II247-256.
37. Tonini T, Rossi F, Claudio PP. 2003; Molecular basis of angiogenesis and cancer. Oncogene 22(42): 6549-6556.
38. van Waarde MA, van Assen AJ, Kampinga HH, et al. 1997; Quantification of transforming growth factor-β in biological material using cells transfected with a plasminogen activator inhibitor-1 promoter-luciferase construct. Anal Biochem 247(1): 45-51.
39. Wang GL, Semenza GL. 1993; Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor 1 DNA-binding activity: implications for models of hypoxia signal transduction. Blood 82(12): 3610-3615.
40. Warren SM, Steinbrech DS, Mehrara BJ, et al. 2001; Hypoxia regulates osteoblast gene expression. J Surg Res 99(1): 147-155. Wong C, Inman E, Spaethe R, et al. 2003; Fibrin-based biomaterials to deliver human growth factors. Thromb Haemost 89(3): 573-582.
41. Woo KJ, Lee TJ, Park JW, et al. 2006; Desferrioxamine, an iron chelator, enhances HIF-1α accumulation via cyclooxygenase-2 signaling pathway. Biochem Biophys Res Commun 343(1): 8-14.
42. Woodbury D, Schwarz EJ, Prockop DJ, et al. 2000; Adult rat and human bone marrow stromal cells differentiate into neurons. J Neurosci Res 61(4): 364-370.
43. Zhao LR, Duan WM, Reyes M, et al. 2002; Human bone marrow stem cells exhibit neural phenotypes and ameliorate neurological deficits after grafting into the ischemic brain of rats. Exp Neurol 174(1): 11-20.